These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30478632)

  • 1. ASO Author Reflections: Safety of Abdominal Surgical Cytoreduction Combined with Locoregional Chemohyperthermia.
    Piso P
    Ann Surg Oncol; 2019 Jan; 26(1):155. PubMed ID: 30478632
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Impact of Operative Technique on Anastomotic Failure During Cytoreductive Surgery for Peritoneal Malignancies-Surgeon Preference is Fine.
    Wiseman JT; Cloyd JM
    Ann Surg Oncol; 2020 Mar; 27(3):793-794. PubMed ID: 31691109
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: The Diminishing Role of Adjuvant HIPEC.
    Enomoto LM; Shen P
    Ann Surg Oncol; 2020 Jan; 27(1):115-116. PubMed ID: 31720936
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and quality outcomes in peritoneal surface malignancy patients: developing a national center for excellence in Colombia.
    Arias F; Herrera-Almario G; Pozo ME; Londoño-Schimmer E; Otero JM; Cardona A; Cortes N; Mora M
    Ann Surg Oncol; 2015 May; 22(5):1733-8. PubMed ID: 25239004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience.
    Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL;
    J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prognostic Model for Predicting Overall Survival in Patients with Peritoneal Surface Malignancy of an Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Ihemelandu C; Fernandez S; Sugarbaker PH
    Ann Surg Oncol; 2017 Aug; 24(8):2266-2272. PubMed ID: 28342015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V
    Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly.
    Huang Y; Alzahrani NA; Alzahrani SE; Zhao J; Liauw W; Morris DL
    World J Surg Oncol; 2015 Aug; 13():262. PubMed ID: 26311565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries.
    Mogal HD; Levine EA; Russell G; Shen P; Stewart JH; Votanopoulos KI
    Ann Surg Oncol; 2016 Feb; 23(2):534-8. PubMed ID: 26289808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
    Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASO Author Reflections: Tending Towards a Personalized Medicine for Colorectal Carcinomatosis by Adding the RAS Mutation Status in the Workup for CRS and HIPEC.
    Arjona-Sanchez A; Rodriguez-Ortiz L
    Ann Surg Oncol; 2019 Aug; 26(8):2605-2606. PubMed ID: 31004296
    [No Abstract]   [Full Text] [Related]  

  • 13. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
    Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J
    Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASO Author Reflections: What is the Best Therapeutic Strategy for Patients with Limited Synchronous Peritoneal Metastases of Colorectal Cancer?
    Mariani A; Goere D
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):818. PubMed ID: 31667730
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
    Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
    Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.
    Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U
    Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.
    Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center.
    Graziosi L; Marino E; De Angelis V; Rebonato A; Donini A
    World J Surg Oncol; 2016 Mar; 14():97. PubMed ID: 27036213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Konstantinidis IT; Chouliaras K; Levine EA; Lee B; Votanopoulos KI
    Ann Surg Oncol; 2017 Dec; 24(13):3825-3830. PubMed ID: 29019118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients.
    Piso P; Nedelcut SD; Rau B; Königsrainer A; Glockzin G; Ströhlein MA; Hörbelt R; Pelz J
    Ann Surg Oncol; 2019 Jan; 26(1):148-154. PubMed ID: 30456672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.